» Articles » PMID: 30532553

In Vitro and in Vivo Superior Radiosensitizing Effect of Berbamine for Head and Neck Squamous Cell Carcinoma

Overview
Publisher Dove Medical Press
Specialty Oncology
Date 2018 Dec 12
PMID 30532553
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Berbamine (BBM), one of the bis-benzylisoquinoline products isolated from , has been demonstrated for its anticancer effect against leukemia, breast cancer, liver cancer, etc. There are some studies focusing on the chemosensitization effect of BBM. However, there is no report about whether BBM could enhance the anticancer effect of radiation, which made us to explore the possible radiosensitization effect of BBM.

Materials And Methods: Here, in vitro cytotoxicity of BBM was evaluated on two kinds of head and neck squamous cancer cell lines. Clonogenic assay was performed to study the radiosensitization effect of BBM. Western blot was utilized to elucidate the possible mechanism underlying the radiosensitization effect.

Results: BBM effectively inhibited the growth of two kinds of cancer cells in a time- and dose-dependent manner. Radiation plus BBM led to significantly more reduction of the colony-forming ability of cancer cells when compared with radiation alone. BBM plus radiation led to the most reduction of STAT3 phosphorylation, followed by the significant decrease of the ratio of Bax/Bcl-2. In vivo study demonstrated that the combinational administration of BBM and radiation generated the most significant tumor-delaying effect among all of the treatment regimens.

Conclusion: We reported, in the current study, the potential role of BBM in not only treating cancer by itself but also offering a promising way to improve the efficacy of radiotherapy by inhibiting the activation of STAT3 and subsequently inducing the apoptosis of cancer.

Citing Articles

The Emerging Role of Natural Products in Cancer Treatment.

Ghosh S, Kumar Das S, Sinha K, Ghosh B, Sen K, Ghosh N Arch Toxicol. 2024; 98(8):2353-2391.

PMID: 38795134 DOI: 10.1007/s00204-024-03786-3.


Role of Plant-Derived Active Constituents in Cancer Treatment and Their Mechanisms of Action.

Khan A, Farooq M, Haseeb M, Choi S Cells. 2022; 11(8).

PMID: 35456005 PMC: 9031068. DOI: 10.3390/cells11081326.


Regulation of Cell-Signaling Pathways by Berbamine in Different Cancers.

Farooqi A, Wen R, Attar R, Taverna S, Butt G, Xu B Int J Mol Sci. 2022; 23(5).

PMID: 35269900 PMC: 8911410. DOI: 10.3390/ijms23052758.


Berbamine Suppresses the Progression of Bladder Cancer by Modulating the ROS/NF-B Axis.

Han C, Wang Z, Chen S, Li L, Xu Y, Kang W Oxid Med Cell Longev. 2021; 2021:8851763.

PMID: 33520087 PMC: 7817266. DOI: 10.1155/2021/8851763.


Proliferation, migration and invasion of triple negative breast cancer cells are suppressed by berbamine via the PI3K/Akt/MDM2/p53 and PI3K/Akt/mTOR signaling pathways.

Liu L, Yan J, Cao Y, Yan Y, Shen X, Yu B Oncol Lett. 2020; 21(1):70.

PMID: 33365081 PMC: 7716707. DOI: 10.3892/ol.2020.12331.


References
1.
Bu X, Zhao C, Wang W, Zhang N . GRIM-19 inhibits the STAT3 signaling pathway and sensitizes gastric cancer cells to radiation. Gene. 2012; 512(2):198-205. DOI: 10.1016/j.gene.2012.10.057. View

2.
Bourhis J, Lapeyre M, Tortochaux J, Rives M, Aghili M, Bourdin S . Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. J Clin Oncol. 2006; 24(18):2873-8. DOI: 10.1200/JCO.2006.08.057. View

3.
Bertrand G, Maalouf M, Boivin A, Battiston-Montagne P, Beuve M, Levy A . Targeting head and neck cancer stem cells to overcome resistance to photon and carbon ion radiation. Stem Cell Rev Rep. 2013; 10(1):114-26. DOI: 10.1007/s12015-013-9467-y. View

4.
Otero D, Poli V, David M, Rickert R . Cutting edge: inherent and acquired resistance to radiation-induced apoptosis in B cells: a pivotal role for STAT3. J Immunol. 2006; 177(10):6593-7. PMC: 2770730. DOI: 10.4049/jimmunol.177.10.6593. View

5.
Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View